[go: up one dir, main page]

ATE414776T1 - FUSION PROTEINS FOR THE SPECIFIC TREATMENT OF CANCER AND AUTOIMMUNE DISEASES - Google Patents

FUSION PROTEINS FOR THE SPECIFIC TREATMENT OF CANCER AND AUTOIMMUNE DISEASES

Info

Publication number
ATE414776T1
ATE414776T1 AT02714638T AT02714638T ATE414776T1 AT E414776 T1 ATE414776 T1 AT E414776T1 AT 02714638 T AT02714638 T AT 02714638T AT 02714638 T AT02714638 T AT 02714638T AT E414776 T1 ATE414776 T1 AT E414776T1
Authority
AT
Austria
Prior art keywords
cancer
fusion proteins
autoimmune diseases
specific treatment
novel therapeutic
Prior art date
Application number
AT02714638T
Other languages
German (de)
Inventor
Mathieu Noteborn
Johan Renes
Ying-Hui Zhang
Original Assignee
Leadd Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leadd Bv filed Critical Leadd Bv
Application granted granted Critical
Publication of ATE414776T1 publication Critical patent/ATE414776T1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rehabilitation Therapy (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to the field of apoptosis. The invention provides novel therapeutic substances, for example novel therapeutic (non-)viral vectors or proteinaceous compounds, that contain apoptin in conjunction with cytotoxic agents, especially in those cases when cells are derailed, such as in cancer- and autoimmune-derived cells.
AT02714638T 2001-03-30 2002-03-28 FUSION PROTEINS FOR THE SPECIFIC TREATMENT OF CANCER AND AUTOIMMUNE DISEASES ATE414776T1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28022901P 2001-03-30 2001-03-30

Publications (1)

Publication Number Publication Date
ATE414776T1 true ATE414776T1 (en) 2008-12-15

Family

ID=23072205

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02714638T ATE414776T1 (en) 2001-03-30 2002-03-28 FUSION PROTEINS FOR THE SPECIFIC TREATMENT OF CANCER AND AUTOIMMUNE DISEASES

Country Status (9)

Country Link
US (1) US20020176860A1 (en)
EP (1) EP1377667B1 (en)
AT (1) ATE414776T1 (en)
AU (1) AU2002246455A1 (en)
DE (1) DE60229924D1 (en)
DK (1) DK1377667T3 (en)
ES (1) ES2321485T3 (en)
PT (1) PT1377667E (en)
WO (1) WO2002079222A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101921820B (en) * 2010-02-10 2013-03-27 赵洪礼 Preparation method of recombinant tumor specificity antiapoptotic factors with activity and application of products thereof
CN101875688B (en) * 2010-02-10 2013-04-17 赵洪礼 Folic acid modification step of method for preparing recombinant tumor specific apoptosis factor and application of products of recombinant tumor specific apoptosis factor
CA2822938A1 (en) 2010-12-27 2012-07-05 Apo-T B.V. A polypeptide that binds aberrant cells and induces apoptosis
JP2014530009A (en) 2011-09-29 2014-11-17 エーピーオー‐ティー ビー．ヴイ． Multispecific binding molecules targeting abnormal cells
EP2802356A1 (en) 2012-01-13 2014-11-19 Apo-T B.V. Aberrant cell-restricted immunoglobulins provided with a toxic moiety

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1188832A1 (en) * 2000-09-08 2002-03-20 Leadd B.V. A delivery method for the tumor specific apoptosis inducing activity of apoptin
EP0878546A1 (en) * 1997-04-15 1998-11-18 Leadd B.V. A gene delivery vehicle expressing the apoptosis-inducing proteins VP2 and/or apoptin
DE69628431T2 (en) * 1995-06-07 2004-05-06 Leadd B.V. USES OF APOPTIN
DE69827805T2 (en) * 1997-08-12 2005-12-15 Leadd B.V. METHOD AND DEVICE FOR DETERMINING THE TRANSFORMATION POTENTIAL OF COMPOUNDS.
MXPA01006998A (en) * 1999-01-11 2002-05-06 Leadd Bv Use of apoptosis inducing agents in the treatment of (auto)immune diseases.
US6962696B1 (en) * 1999-10-04 2005-11-08 Vion Pharmaceuticals Inc. Compositions and methods for tumor-targeted delivery of effector molecules
EP1186665A1 (en) * 2000-09-08 2002-03-13 Leadd B.V. A delivery method for the tumor specific apoptosis inducing activity of apoptin
WO2002085305A2 (en) * 2001-04-24 2002-10-31 Washington University Compositions and methods for inducing cancer cell death

Also Published As

Publication number Publication date
AU2002246455A1 (en) 2002-10-15
WO2002079222A2 (en) 2002-10-10
WO2002079222A3 (en) 2003-05-08
DE60229924D1 (en) 2009-01-02
EP1377667A2 (en) 2004-01-07
US20020176860A1 (en) 2002-11-28
DK1377667T3 (en) 2009-03-30
ES2321485T3 (en) 2009-06-08
PT1377667E (en) 2009-03-13
EP1377667B1 (en) 2008-11-19

Similar Documents

Publication Publication Date Title
EP1194164B8 (en) Prion protein peptides and uses thereof
TR200301846T2 (en) Cripto-blocking Antibodies and their use.
DK1368060T3 (en) HMGB1 protein inhibitors and / or antagonists for the treatment of vascular disease
ATE314095T1 (en) VIRUS-LIKE PARTICLES FOR INDUCING AUTOANTIBODIES
TR200102191T2 (en) HER-2 / neu fusion proteins.
DE60224291D1 (en) SYSTEM FOR ANTIBODY EXPRESSION AND SYNTHESIS
CY1108489T1 (en) MANUFACTURE OF CATALOGS
CY1112055T1 (en) COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF LUNG TUMOR
ATE409181T1 (en) PROTEOMIMETIC COMPOUNDS AND METHODS
ATE242633T1 (en) DIALKYLFUMARATE FOR THE TREATMENT OF AUTOIMMUNE DISEASES
ATE507839T1 (en) COMBINATION THERAPY
EA200300845A1 (en) MODIFIED ANTIBODIES AND METHODS OF APPLICATION
DE60201783D1 (en) Pharmaceutical composition containing non-MHC-dependent T cells / NK cells and MHC-dependent cells for the treatment of tumors
DE602004001857D1 (en) THIENOPYRIMIDINDIONES AND THEIR USE IN THE MODULATION OF AUTOIMMUNE DISEASES
DE60034957D1 (en) Compositions and Methods for Modulating Apoptosis in Cells Expressing BC1-2 Family Proteins
EA200601738A1 (en) MODIFIED PROTEINS OF BOUGHINE, CYTOTOXINES AND METHODS OF THEIR APPLICATION
DE60021381D1 (en) CHINONIC COMPOUNDS FOR THE TREATMENT OF DISEASES
DE60204224D1 (en) USE OF CERTAIN SUBSTITUTED PYRROLIDONE SUCH AS FOR EXAMPLE. PIRACETAM IN THE TREATMENT OF VIRALS AND OTHER DISEASES
ATE343398T1 (en) COMPOSITIONS AND METHODS FOR TREATING HYPERIMMUNE REACTIONS IN THE EYE
DE60229924D1 (en) FUSION PROTEINS FOR THE SPECIFIC TREATMENT OF CANCER AND AUTOIMMUNE DISEASES
ATE310828T1 (en) IMPLANT AND VECTOR FOR THE TREATMENT OF ACQUIRED DISEASES
GB0004576D0 (en) Proteins
WO2001007479A3 (en) Fragments of cellular prion protein and methods useful in the diagnosis and treatment of prion diseases
DE60143074D1 (en) IMMUNOMODULATION WITH RECEPTOR-INDUCED DEATH BY APOPTOSIS
ATE505538T1 (en) DNA VECTORS

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1377667

Country of ref document: EP

REN Ceased due to non-payment of the annual fee